Abstract:Objective To investigate the efficacy of beclomethasone propionate combined with salbutamol sulfate nebulization for the treatment of bronchopneumonia and risk factors for morbidity in children. Methods A total of 120 children with bronchopneumonia treated in our hospital from March 2019 to February 2020 were selected as disease group,and they were divided into control group and observation group randomly (n=60,each).Symptomatic treatment and nebulization of salbutamol sulphate were adopted in control group and observation group for 7 days,based on which beclomethasone propionate was combined in the observation group.Differences in treatment efficacy,lung function,bone metabolic indexes,clinical symptom improvement,and adverse effects between the two groups of children were compared. Results Children in the observation group had a significantly higher treatment response rate than those in the control group (91.67% vs 78.33%,χ2=4.182,P<0.05).After treatment,FEV,FEV1 as well as FEV1% were significantly higher in both child groups,and these in the observation group were significant higher than those in the control group (P<0.05).Before and after treatment,there was no statistically significant difference in S-Ca,S-P as well as ALP between the observation group and control group (P>0.05).Time to disappearance of fever,disappearance of cough,disappearance of pulmonary rales,and hospital stay were significantly lower in the observation group than in the control group (P<0.05).There was no significant difference in the incidence of adverse reactions (such as diarrhea,rash,rapid heart rate) between the two groups during treatment (P>0.05). Conclusion Beclomethasone propionate combined with salbutamol sulphate nebulisation for the treatment of bronchopneumonia is highly effective.